SCHEDULE: EcoR1 Capital Boosts Stake in Atara Biotherapeutics to 9.9%

EcoR1 Capital, LLC and its affiliates have disclosed a significant beneficial ownership stake of 9.9% in Atara Biotherapeutics, Inc. common stock.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have jointly filed an amendment to their Schedule 13G.
• EcoR1 Capital, LLC and Oleg Nodelman each beneficially own 715,853 shares of Atara Biotherapeutics, Inc. common stock, representing 9.9% of the class.
• EcoR1 Capital Fund Qualified, L.P. beneficially owns 667,639 shares, representing 9.3% of the class.
• The percentage ownership is calculated based on 7,023,032 shares of Common Stock outstanding on August 6, 2025, as reported in the Issuer's Form 10-Q for the quarter ended June 30, 2025.
• The beneficial ownership includes both currently held common stock and warrants to acquire additional shares, subject to a 9.99% beneficial ownership limitation.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Atara Biotherapeutics, Inc., other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a significant, stable institutional ownership stake by a specialized healthcare investor like EcoR1 Capital is generally viewed positively, indicating investor confidence in Atara Biotherapeutics. The explicit disclaimer of intent to influence control also reduces potential concerns about activist pressure.

Positives

• A significant institutional investor, EcoR1 Capital, maintains a substantial stake in Atara Biotherapeutics, indicating continued confidence in the company.
• The beneficial ownership includes warrants, suggesting a long-term investment perspective and potential for increased equity stake.

Risks

• The filing explicitly states that the securities were not acquired for the purpose of changing or influencing control, mitigating immediate activist investor concerns, but a large stake always carries potential for future influence.

Future Outlook

The filing is a disclosure of current ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's future performance.

Industry Context

EcoR1 Capital is a healthcare-focused investment firm, and its significant stake in Atara Biotherapeutics, a biotechnology company, aligns with its investment strategy in the life sciences sector. Such disclosures are common for institutional investors taking substantial positions in public companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may provide a level of confidence to other investors, signaling that a sophisticated investor sees value in Atara Biotherapeutics. It also highlights a substantial block of shares held by a single entity/group.

Key Dates

Keywords

Atara Biotherapeutics, EcoR1 Capital, Oleg Nodelman, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Investment, Institutional Investor